Yang Zhihui, Zhou Peng, Wang Liping, Yang Xiao, Yang Mengqi, Xia Jiazeng
Department of General Surgery, Institute of General Surgical Research, Jiangnan University Medical Center (Wuxi No.2 People's Hospital), School of Medicine, Wuxi, China.
Department of General Surgery, People's Hospital of Nanjing Medical University, Wuxi, China.
World J Surg Oncol. 2025 May 29;23(1):204. doi: 10.1186/s12957-025-03866-3.
The E3 ubiquitin ligase HECW1 was found to be involved in ubiquitination modifications during malignant progression of multiple tumors. However, the prognostic role of HECW1 expression in gastric cancer (GC) remains unclear.
The Tumor Immunoassay Resource (TIMER2.0) system evaluated the association of HECW1 with tumor-infiltrating lymphocytes in carcinomas. The UALCAN assessed HECW1 mRNA expression levels in GC tissues and examined their associations with clinicopathological characteristics. The Kaplan Meier-plotter analyzed the effect of HECW1 on the survival of GC patients. The cBioPortal retrieved information about genetic variants in HECW1 gene. Protein‒protein interaction (PPI) networks associated with HECW1 were explored using the STRING database. The functional effects of HECW1 on GC cells were evaluated through proliferation (Cell Counting Kit-8), apoptosis (Flow cytometry), and migration (Transwell and wound healing assays). The RNA-Seq was applied to explore the underlying mechanisms.
HECW1 demonstrated significant overexpression in GC tumor tissues, correlating with adverse clinical outcomes. Clinically, elevated HECW1 expression exhibited an inverse association with tumor-infiltrating CD8 T lymphocytes while demonstrating a positive correlation with macrophages, DCs, and neutrophils infiltration, suggesting its potential involvement in tumor immune evasion mechanisms. Functional validation revealed that HECW1 knockdown markedly suppressed GC cell proliferation and migratory capacity, concurrently promoting apoptotic cell death. Mechanistic investigations identified that HECW1 exerts its oncogenic effects through dysregulation of the Hippo signaling pathway, with its silencing effectively attenuating tumor progression via pathway modulation.
HECW1 upregulation is significantly associated with poor prognosis and immune infiltration in GC patients, emphasizing its potential as a prognostic biomarker.
E3泛素连接酶HECW1被发现参与多种肿瘤恶性进展过程中的泛素化修饰。然而,HECW1表达在胃癌(GC)中的预后作用仍不清楚。
肿瘤免疫分析资源(TIMER2.0)系统评估了HECW1与癌组织中肿瘤浸润淋巴细胞的相关性。UALCAN评估了GC组织中HECW1 mRNA表达水平,并检查了它们与临床病理特征的相关性。Kaplan Meier绘图仪分析了HECW1对GC患者生存的影响。cBioPortal检索了有关HECW1基因遗传变异的信息。使用STRING数据库探索与HECW1相关的蛋白质-蛋白质相互作用(PPI)网络。通过增殖(细胞计数试剂盒-8)、凋亡(流式细胞术)和迁移(Transwell和伤口愈合试验)评估HECW1对GC细胞的功能影响。应用RNA测序探索潜在机制。
HECW1在GC肿瘤组织中显著过表达,与不良临床结果相关。临床上,HECW1表达升高与肿瘤浸润性CD8 T淋巴细胞呈负相关,而与巨噬细胞、树突状细胞和中性粒细胞浸润呈正相关,表明其可能参与肿瘤免疫逃逸机制。功能验证表明,HECW1敲低显著抑制GC细胞增殖和迁移能力,同时促进凋亡细胞死亡。机制研究发现,HECW1通过失调Hippo信号通路发挥其致癌作用,其沉默通过通路调节有效减弱肿瘤进展。
HECW1上调与GC患者的不良预后和免疫浸润显著相关,强调了其作为预后生物标志物的潜力。